What Is Orforglipron (Foundayo)?
Orforglipron — now sold under the brand name Foundayo — is Eli Lilly's once-daily oral GLP-1 receptor agonist small molecule, FDA approved on April 1, 2026 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Unlike semaglutide (Ozempic), which exists in an oral form (Rybelsus) but requires fasting administration and has lower bioavailability, orforglipron is a true non-peptide small molecule that can be taken with or without food and achieves consistent systemic absorption.
Foundayo became available via LillyDirect on April 6, 2026 and quickly expanded to retail pharmacies and telehealth platforms. It is the first non-peptide oral GLP-1 receptor agonist approved in the United States and the first NME approved under the FDA's Commissioner's National Priority Voucher (CNPV) program — approved just 50 days after NDA filing. Its approval came after Pfizer's competing oral GLP-1 (danuglipron) was discontinued in April 2025 due to a hepatic safety signal. Phase 3 ATTAIN trial data showed Foundayo beat AstraZeneca's Farxiga and matched or surpassed Novo Nordisk's semaglutide for HbA1c reduction in head-to-head diabetes trials. The T2D indication NDA is expected to be filed with the FDA in 2026.
ATTAIN Trial Program (Orforglipron)
The ATTAIN program is orforglipron's Phase 3 trial series, including studies in type 2 diabetes (multiple ATTAIN-T2D studies) and obesity (ATTAIN-OBESITY). Key highlights:
- Orforglipron has now been submitted to the FDA for T2D and is expected to be reviewed for obesity as well.
- Phase 3 ATTAIN-1 data (August 2025 readout) showed 12.4% weight loss in adults with obesity — meaningful, but substantially less than retatrutide's 28.7% signal. Source: Lilly PR Newswire, August 7 2025.
- The drug outperformed semaglutide on HbA1c reduction in a head-to-head T2D comparison, positioning it as a strong diabetes option.
- Head-to-head vs retatrutide data does not exist and is unlikely in the near term — the two products serve different patient segments.
Why Would Lilly Develop Both?
At first glance it might seem odd that Lilly is pursuing both an ultra-high-efficacy injectable (retatrutide) and an oral convenience drug (orforglipron) simultaneously. But this is intentional market segmentation:
- Retatrutide targets the high-need, high-efficacy segment: Patients who need maximum weight loss (BMI ≥40, severe comorbidities), those who have failed on tirzepatide or semaglutide, or high-compliance patients willing to use injectables for superior outcomes.
- Orforglipron targets the broader access segment: Patients who are needle-averse, those in markets where injectable cold-chain supply is difficult, patients who prefer a daily pill, or those seeking a first-line oral option. The lower efficacy is acceptable as a trade-off for convenience.
Lilly's strategy mirrors the pattern in diabetes (Mounjaro injectable vs oral semaglutide-type competitors) — offering a high-efficacy option and a convenient option to different market segments. Truist Securities has estimated Lilly's obesity trio (Mounjaro, Zepbound, and orforglipron) could reach $101 billion in peak worldwide sales — a number that rises further if retatrutide is approved.
Which Launched First?
Foundayo (orforglipron) is already on the market. It received FDA approval on April 1, 2026 and launched commercially via LillyDirect on April 6, 2026 — making it the nearer-term option for patients today. Retatrutide is still completing Phase 3 TRIUMPH trials: the pivotal TRIUMPH-1 trial (n=2,339, general obesity) reported 28.3% weight loss at 80 weeks on May 21, 2026, but no NDA has yet been filed. Analyst consensus projects NDA submission in Q4 2026 or Q1 2027 and potential FDA approval in mid-to-late 2027 (estimate, not Lilly-confirmed). Source: Lilly PR Newswire, August 7 2025.
For patients: Foundayo is available today. Retatrutide remains investigational — the longer-term, higher-efficacy alternative for patients who need bariatric-surgery-level weight loss in an injectable format.
Foundayo (Orforglipron) FDA Approval: April 1, 2026
In a landmark regulatory event, the FDA approved Foundayo (orforglipron) for chronic weight management on April 1, 2026 — the first new molecular entity ever approved under the Commissioner's National Priority Voucher (CNPV) program. The approval came just 50 days after Lilly's NDA filing on January 20, 2026, versus the standard 10-month PDUFA review period. It is the fastest NME approval since 2002. The drug is indicated for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Foundayo was available via LillyDirect starting April 6, 2026, with retail pharmacy and telehealth access following shortly after. Source: FDA press release, April 1, 2026.
This approval reshapes the comparison with retatrutide. Previously, this page described both drugs as pre-market. That is no longer accurate: Foundayo is a commercially available product; retatrutide remains investigational. Patients and clinicians making decisions today can access Foundayo; retatrutide access remains within clinical trials only.
ATTAIN-1 Obesity Results: 12.4% at 72 Weeks
The ATTAIN-1 Phase 3 trial (NCT05869903) is the pivotal obesity study for Foundayo. Results announced August 7, 2025 and published in the New England Journal of Medicine in September 2025 showed that the highest dose (36 mg) produced 12.4% mean weight loss at 72 weeks (equivalent to 27.3 lbs / 12.4 kg on average) in adults with obesity or overweight without type 2 diabetes. Nearly 60% of participants on the 36 mg dose achieved ≥10% body weight reduction — the threshold considered clinically meaningful for most obesity comorbidities including hypertension, dyslipidemia, sleep apnea, and cardiovascular risk. Source: Lilly PR Newswire, August 7, 2025.
Critically, no hepatic safety signal was observed — a meaningful differentiator from Pfizer's danuglipron, which was discontinued in April 2025 due to liver enzyme elevations. The GI adverse event profile (nausea, diarrhea, constipation) was consistent with the injectable GLP-1 class and managed with standard dose titration. A notable secondary finding: among participants with prediabetes at baseline, up to 91% of Foundayo participants achieved near-normal blood sugar levels versus 42% with placebo.
Retatrutide TRIUMPH-1 Phase 3 Topline: 28.3% at 80 Weeks
The pivotal TRIUMPH-1 trial (NCT05929066, n=2,339 adults with obesity, no T2D) reported topline results on May 21, 2026. At the highest dose (12 mg), retatrutide produced 28.3% mean weight loss at 80 weeks — approximately 70.3 lbs lost on average. This is the largest Phase 3 weight loss result ever reported for a pharmacological treatment, matching or exceeding average outcomes from bariatric sleeve gastrectomy. Among participants on the 12 mg dose: 62.5% lost ≥25% of body weight, 45.3% lost ≥30%, and 65.3% fell below BMI 30 (out of the obesity range) — including more than one-third of those who started with BMI ≥40. Sources: Medscape, May 21, 2026; RemyPeptides, June 21, 2026.
Despite these results, no NDA has been filed as of June 2026. TRIUMPH-2 (T2D population) and TRIUMPH-3 (obesity + established CVD) are still reading out in mid-to-late 2026. Lilly needs the full data package before FDA submission, which is projected for Q4 2026 or Q1 2027.
Injection vs. Pill: Patient Choice Reality
Surveys show needle aversion is a clinically significant barrier to GLP-1 therapy uptake. A January 2026 survey of 2,000 overweight adults found that 30% of people who have never tried GLP-1s cited injections as a reason not to start, and 22% of former users named injections as the primary reason for stopping. Notably, 87% of current injectable GLP-1 users expressed interest in switching to an oral option. Source: Yahoo Finance / Sunlight.com Survey, January 16, 2026.
Foundayo's practical advantages compound this: it is a once-daily tablet taken with or without food, with no cold-chain storage requirements, no injection technique training, and no sharps disposal. Unlike oral semaglutide (Rybelsus), it does not require a 30-minute fasting window. These factors matter especially for frequent travelers, patients with dexterity limitations, and those in lower-resource settings. The trade-off is real: 12.4% weight loss versus retatrutide's projected ~28%. For patients with moderate obesity (BMI 30–35) and no urgent comorbidities, that gap may be acceptable in exchange for convenience and lower cost. For patients with BMI ≥40, severe metabolic disease, or prior GLP-1 failure, retatrutide's additional glucagon receptor activity — which uniquely drives thermogenesis and ~20% LDL reduction — may be worth the wait and the needle.
Cost Realities: Foundayo Confirmed, Retatrutide Unknown
Foundayo launched at a notably accessible price point, partly due to a November 2025 agreement between Eli Lilly and the Trump administration as a condition for the accelerated CNPV regulatory review. Self-pay pricing via LillyDirect starts at $149/month for the starter dose and reaches $299–$349/month for maintenance doses. Patients with commercial insurance who use the Foundayo Savings Card pay approximately $25/month. Medicare Part D coverage under the GLP-1 Bridge program is expected to bring costs to approximately $50/month from July 1, 2026. Sources: NowPatient, April 2, 2026; CNN, April 1, 2026.
Retatrutide has no announced US pricing as of June 2026 and cannot be priced until FDA approval. Analysts suggest it will carry a premium over Zepbound ($499–550/month LillyDirect), given its superior efficacy — likely in the $400–600+ range self-pay. The practical effect: Foundayo is accessible today at $149–349/month; retatrutide is not yet available at any price. For cost-sensitive patients with adequate response to 12.4% weight loss, Foundayo represents a meaningful option now rather than waiting 18–24 months for retatrutide approval.
Who Should Watch Which Drug?
- Watch retatrutide if: You need maximum weight loss efficacy, are comfortable with weekly injections, have had insufficient response to tirzepatide, or have conditions that benefit from glucagon receptor agonism (liver fat, energy expenditure).
- Watch orforglipron if: You prefer an oral daily pill, are needle-averse, want a first-line oral GLP-1 option, or need a drug that can be used in settings with limited cold-chain infrastructure.